With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues to evolve. To date, the MS market has accommodated many options owing to disease heterogeneity, individualized treatment decisions, and the unique clinical profile that defines each DMT. That said, with each new launch and growing generics competition, the market is becoming increasingly crowded; meanwhile, early intervention with high-efficacy drugs continues to gain traction in lieu of treatment escalation, the prevailing paradigm. Thus, players engaged in or entering this space must assess where their products, especially next-in-class alternatives, will fit. This national patient-level claims data analysis explores treatment progression by line of therapy, persistence and compliance by brand, and the positioning of current DMTs.
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis.
Key companies: Bayer, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Mylan / Viatris, Novartis, Sanofi, Teva.
Key drugs covered: Aubagio, Bafiertam, Copaxone / glatiramer acetate, Gilenya, interferons, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Ponvory, Tecfidera / dimethyl fumarate, Tysabri, Vumerity, Zeposia.
Key analysis provided:
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.